Oppenheimer assumed coverage of Insulet (PODD) with an Outperform rating and price target of $365, up from $324. The firm updated the company’s model post the Q2 report. Insulet has several new near-term catalysts, including the launch of its Omnipod 5 insulin pump and international expansion, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet promotes Eric Benjamin to COO, names Manoj Raghunandanan CGO
- Insulet price target raised to $300 from $266 at Barclays
- 3 “Strong Buy” Growth Stocks to Buy Now, 8/12/2025, According to Analysts
- Insulet price target raised to $360 from $350 at Baird
- Insulet price target raised to $350 from $330 at RBC Capital